Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting
- 1 January 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 6 (1) , 12-18
- https://doi.org/10.1200/jop.091058
Abstract
Results of this study suggest that treating patients according to evidence-based guidelines is a cost-effective strategy for delivering care to those with non–small-cell lung cancer treated in the outpatient community setting.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacoeconomic Evaluations in the Treatment of Non-Small Cell Lung CancerDrugs, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals of Oncology, 2006
- Using propensity scores to estimate the cost–effectiveness of medical therapiesStatistics in Medicine, 2005
- Evaluating The Efficiency Of California Providers In Caring For Patients With Chronic IllnessesHealth Affairs, 2005
- Lung Cancer: A Cost and Outcome Study Based on Physician Practice PatternsDisease Management, 2004
- The Implications of Regional Variations in Medicare Spending. Part 1: The Content, Quality, and Accessibility of CareAnnals of Internal Medicine, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Vinorelbine in Advanced Non???Small Cell Lung CancerPharmacoEconomics, 1999
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994